Official ESCRS | European Society of Cataract & Refractive Surgeons
Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Posters

Search Title by author or title

Investigation into the clinical outcomes of aspheric, hydrophilic acrylic trifocal intraocular lens

Poster Details

First Author: E. Law UNITED KINGDOM

Co Author(s):    R. Aggarwal   H. Kasaby   H. Buckhurst   P. Buckhurst           

Abstract Details

Purpose:

To determine the visual outcomes of an aspheric, hydrophilic acrylic trifocal Intraocular lens at 3-6 months post-operatively.

Setting:

BMI Southend Hospital

Methods:

Subjects who were bilateral implanted with an acrylic hydophillic aspheric trifocal IOL were enrolled in the study. At 3-6 months; uncorrected distance (UCDVA) and near (UCNVA) visual acuity; best distance corrected distance (BCDVA), intermediate (BCIVA) and near (BCNVA) visual acuity; contrast sensitivity (CSV1000); Defocus curves; critical print size (CPS); subjective perception of visual quality (NAVQ and QoV); and glare (Zeiss glare simulator) were assessed.

Results:

The study enrolled twenty-six subjects (mean age 59±7yrs). The mean visual acuity values at 3-6 months were UCVA 0.01±0.08, UCNVA 0.22±0.10, BCVA -0.02±0.07, BCNVA 0.18±0.09 and BCIVA 0.23±0.12; Contrast sensitivity was 1.68±0.15 at 3cpd, 1.91±0.18 at 6cpd, 1.85±0.22 at 12cpd, and 1.69±0.16 at 18 cpd; CPS was 0.30±0.08 LogRAD; The defocus curves demonstrated a peak in acuity at the -1.50 (intermediate) and -3.00 (near) magnitudes of defocus. The subjective perception of the quality of near vision was high with a mean NAVQ score of 16.2±14.8.

Conclusions:

Post-operative visual acuity at distance intermediate and near was excellent. Contrast sensitivity was preserved across spatial frequencies and subjects were satisfied with their reading vision post-implantation.

Financial Disclosure:

NONE

Back to Poster listing